Research programme: bioscavenger proteins - Bolder BioTechnology
Latest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator Bolder BioTechnology
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Poisoning
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Poisoning in USA
- 10 Oct 2005 Preclinical trials in Poisoning in USA (unspecified route)